Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

著者: Chi, Zhihong, Li, Siming, Sheng, Xinan, Si, Lu, Cui, Chuanliang, Han, Mei, Guo, Jun
出版事項 2011

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

著者: Li, Siming, Kong, Yan, Si, Lu, Chi, Zhihong, Cui, Chuanliang, Sheng, Xinan, Guo, Jun
出版事項 2014

Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

著者: Xu, Longwen, Cheng, Zhiyuan, Cui, Chuanliang, Wu, Xiaowen, Yu, Huan, Guo, Jun, Kong, Yan
出版年 J Transl Med (2019)

Correction to: Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

著者: Xu, Longwen, Cheng, Zhiyuan, Cui, Chuanliang, Wu, Xiaowen, Yu, Huan, Guo, Jun, Kong, Yan
出版年 J Transl Med (2019)

Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images

著者: Hu, Jing, Cui, Chuanliang, Yang, Wenxian, Huang, Lihong, Yu, Rongshan, Liu, Siyang, Kong, Yan
出版年 Transl Oncol (2020)

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma

著者: Dai, Jie, Wu, Shan, Kong, Yan, Chi, Zhihong, Si, Lu, Sheng, Xinan, Cui, Chuanliang, Fang, Jing, Zhang, Jue, Guo, Jun
出版年 Sci Rep (2017)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis

著者: Sheng, Xinan, Chi, Zhihong, Cui, Chuanliang, Si, Lu, Li, Siming, Tang, Bixia, Mao, Lili, Lian, Bin, Wang, Xuan, Yan, Xieqiao, Guo, Jun
出版年 Oncotarget (2016)

TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma

著者: Yu, Sifan, Xu, Tianxiao, Dai, Jie, Ma, Meng, Tang, Huan, Chi, Zhihong, Si, Lu, Cui, Chuanliang, Sheng, Xinan, Kong, Yan, Guo, Jun
出版年 Onco Targets Ther (2018)

Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients

著者: Wang, Xuan, Kong, Yan, Chi, Zhihong, Sheng, Xinan, Cui, Chuanliang, Mao, Lili, Lian, Bin, Tang, Bixia, Yan, Xieqiao, Si, Lu, Guo, Jun
出版年 Thorac Cancer (2019)

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma

著者: Yu, Sifan, Dai, Jie, Ma, Meng, Xu, Tianxiao, Kong, Yan, Cui, Chuanliang, Chi, Zhihong, Si, Lu, Tang, Huan, Yang, Lu, Sheng, Xinan, Guo, Jun
出版年 Cell Death Dis (2019)

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma

著者: Cui, Chuanliang, Xu, Canqiang, Yang, Wenxian, Chi, Zhihong, Sheng, Xinan, Si, Lu, Xie, Yihong, Yu, Jinyu, Wang, Shun, Yu, Rongshan, Guo, Jun, Kong, Yan
出版年 NPJ Genom Med (2021)

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma

著者: Wu, Xiaowen, Yan, Junya, Dai, Jie, Ma, Meng, Tang, Huan, Yu, Jiayi, Xu, Tianxiao, Yu, Huan, Si, Lu, Chi, Zhihong, Sheng, Xinan, Cui, Chuanliang, Kong, Yan, Guo, Jun
出版年 Oncol Lett (2017)

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

著者: Yu, Jiayi, Wu, Xiaowen, Yan, Junya, Yu, Huan, Xu, Longwen, Chi, Zhihong, Sheng, Xinan, Si, Lu, Cui, Chuanliang, Dai, Jie, Ma, Meng, Xu, Tianxiao, Kong, Yan, Guo, Jun
出版年 J Hematol Oncol (2018)

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

著者: Wu, Xiaowen, Yu, Jiayi, Yan, Junya, Dai, Jie, Si, Lu, Chi, Zhihong, Sheng, Xinan, Cui, Chuanliang, Ma, Meng, Tang, Huan, Xu, Tianxiao, Yu, Huan, Kong, Yan, Guo, Jun
出版年 Cancer Biol Ther (2018)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy

著者: Wang, Xuan, Xu, Weiran, Chi, Zhihong, Si, Lu, Sheng, Xinan, Kong, Yan, Zhou, Li, Mao, Lili, Lian, Bin, Tang, Bixia, Yan, Xieqiao, Bai, Xue, Cui, Chuanliang, Guo, Jun
出版年 Transl Oncol (2020)

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials

著者: Zhou, Li, Wang, Xuan, Chi, Zhihong, Sheng, Xinan, Kong, Yan, Mao, Lili, Lian, Bin, Tang, Bixia, Yan, Xieqiao, Bai, Xue, Li, Siming, Guo, Jun, Cui, Chuanliang, Si, Lu
出版年 Front Immunol (2021)

A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma

著者: Cui, Chuanliang, Mao, Lili, Chi, Zhihong, Si, Lu, Sheng, Xinan, Kong, Yan, Li, Siming, Lian, Bin, Gu, Kangsheng, Tao, Min, Song, Xin, Lin, Tongyu, Ren, Xiubao, Qin, Shukui, Guo, Jun
出版事項 2013

Clinical significance of BRAF(V600E) mutation in circulating tumor DNA in Chinese patients with melanoma

著者: Tang, Huan, Kong, Yan, Si, Lu, Cui, Chuanliang, Sheng, Xinan, Chi, Zhihong, Dai, Jie, Yu, Sifan, Ma, Meng, Wu, Xiaowen, Yu, Jiayi, Xu, Tianxiao, Yu, Huan, Yan, Junya, Guo, Jun
出版年 Oncol Lett (2018)

Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma

著者: Yan, Junya, Yu, Jiayi, Wu, Xiaowen, Xu, Tianxiao, Yu, Huan, Dai, Jie, Ma, Meng, Tang, Huan, Xu, Longwen, Chi, Zhihong, Si, Lu, Sheng, Xinan, Cui, Chuanliang, Kong, Yan, Guo, Jun
出版年 J Cancer (2018)

High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis

著者: Xu, Tianxiao, Ma, Meng, Chi, Zhihong, Si, Lu, Sheng, Xinan, Cui, Chuanliang, Dai, Jie, Yu, Sifan, Yan, Junya, Yu, Huan, Wu, Xiaowen, Tang, Huan, Yu, Jiayi, Kong, Yan, Guo, Jun
出版年 Cancer Sci (2018)